Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 ...

Although presymptomatic T1D (Stages 1 and 2) can be detected months or years before symptoms appear, most people are not diagnosed until they feel unwel. 10 11 Over the past 50 years, scientists ...

In the annual diversity, equity and inclusion (DE&I) Report, Sanofi takes stock of progress on the three pillars of the DE&I strategy. On the ‘building representative leadership’ pillar: 45%1 of ...

In many countries, minimum wages are insufficient to guarantee that workers and their families can meet basic needs. Sanofi is proud to go beyond the minimum by committing to a living wage for all ...

Since January 1, 2024, the program's flagship measure - 12 months' salary, social protection and employment guarantee - has been in place for all employees affected by cancer, regardless of their ...

Third quarter 2024 results were reviewed by management during a conference call with the financial community on Friday October 25, 2024. The presentation was followed by a Q&A session. We’re proud to ...

A booster to transform breakthrough technologies and processes developed by best-in-class academic partners and start-ups into innovative solutions to accelerate our R&D portfolio. In 2022, the ...

Sanofi has a hybrid workplace where employees decide how they want to work. We realise the value of diversity and offer a range of benefits for the health of our employees and their families We work ...